SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02009826
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects
Previous research has suggested central nervous system inflammatory activity to be critically involved in disease development and progression in schizophrenia, with a complex interplay of inflammatory mechanisms leading to the development of brain abnormalities and medical symptoms related to schizophrenia. However, the mutual interactions of different inflammatory pathways and their relation to disease course have not been sufficiently studied. This study therefore aims to explore the interaction of neuroinflammatory mechanisms in patients with schizophrenia and to assess whether the inflammatory activity in schizophrenia is state-dependent and occurs mainly during psychotic episodes.
NCT02009826 Schizophrenia Psychosis MeSH:Schizophrenia Psychotic Disorders Mental Disorders
HPO:Psychosis Schizophrenia
3 Interventions
Name: [18F]-PBR111 Positron Emission Tomography (PET)
Name: Cognitive and psychomotor tasks
Name: Blood sampling
Primary Outcomes
Description: Regional distribution volume in tissue (VT) of 2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide (PBR111) labelled with fluorine-18 (18F) in schizophrenia patients and age- , gender-, and translocator protein (TSPO) binding profile- matched healthy controls
Measure: Regional VT of [18F]PBR111 Time: 2 yearsSecondary Outcomes
Description: Levels and ratios of inflammatory and neurotoxicity markers in blood samples of schizophrenia patients compared to healthy age- and gender-matched healthy controls.
Measure: Peripheral markers Time: 2 yearsTime Perspective: Prospective
Case-Control
There is one SNP
SNPs
1 rs6971
- Low affinity binder of the TSPO, as determined by rs6971 polymorphism genotyping at Screening - Use of benzodiazepines for 3x the half-life prior to PET-scan - Presence of irremovable magnetic materials in or on the body - Has a medical history of organic brain disease - Has a medical history of traumatic brain injury - Has a medical history of allergic reaction to any of the substances in the tracer fluid.